AstraZeneca and Daiichi Sankyo’s HER2-targeting drug ‘Enhertu’ may be the answer to HER2-low breast cancers.
The study showed results of their drug reducing the risk of cancer or worsening it by killing nearly half of it. Previously, the patients who were considered out of reach for a targeted therapy can now be treated by Enhertu. This FDA-approved drug can also be expanded for other breast cancer patients.
Read More from MedCity News
According to Business Wire, global Healthcare Industry will be worth $12T by 2022. Healthcare is vast and highly fragmented with a mix of public and private players. It comprises patients and healthcare providers such as hospitals, pharmaceuticals, and related life sciences.
Digitisation and Post-Covid world are set to transform the healthcare industry in the coming decade. Our weekly business newsletter covers innovations and disruptions in the Healthcare industry with global coverage.
HealthGeniuses is managed by IndustryGeniuses (A place where industries meet innovation). We are rolling out content platforms for the world’s hottest industries such as Food & Grocery Retail, Consumer Goods and Healthcare. For each of these key industries, we support Tech Startups and Industry Disruptors as they roll out next generation digital initiatives.
IndustryGeniuses team brings practical domain knowledge of working with 300+ tech startups and brands over the past decade.